Sweden’s Minister of Industry breaks ground and Fujirebio as the first new tenant
Sweden’s Minister of Business, Industry, and Innovation breaks ground on the first new building in GoCo Health Innovation City and welcomes Japanese cancer diagnostics company Fujirebio as the first new tenant.
GoCo Health Innovation City has a vision to be Sweden's largest life science cluster. Co-developed by Next Step, Vectura Properties, and AstraZeneca, the 100,000 square-meter campus aims to house 350 large and small companies, as well as researchers and students. In total, the cluster will have more than 7,000 workspaces.
The first new building will be a state-of-the-art laboratory building for diagnostics development, with 8,000 square meters tailor made for new tenant Fujirebio. Fujirebio is part of Miraca Group, a global group based in Japan. Representatives from GoCo Health Innovation City and Fujirebio met at the Swedish Embassy in Tokyo last week to sign the agreements formally.
“Our vision is to continue to expand globally. Good partnership and collaboration are the key to innovation and GoCo Health Innovation City is the perfect place for us to establish new partnerships. The concept and the community will also help us to attract new talent, which is another positive benefit for our company. We look forward to growing in Sweden and I hope that our relations with Sweden will be strengthened,” says Goki Ishikawa, President & CEO, Fujirebio Inc.
“Innovative solutions for better care and health require a thorough understanding of unmet medical needs, but also close collaboration between caregivers, academic researchers, the pharmaceutical industry, and the diagnostic industry. That's exactly what GoCo Health Innovation City offers us,” says Christina Hall, CEO of Fujirebio Diagnostics.
Big and small companies now see the benefits of different players sitting together in new collaborative environments. Strong examples of this include the mobility cluster created at Lindholmen in Gothenburg.
“We are inclusive and will strengthen an already strong life science region by providing new opportunities to collocate and collaborate. Other examples around the world have demonstrated that when industry segments come together, they gain competitive advantages in the long term. The fact that Fujirebio selected us proves that we have a competitive product that is on the right path,” says Peder Wahlgren, CEO of GoCo Development AB.
“It is through collaboration that we can strengthen Sweden's competitiveness and our leadership in innovation, and at the same time meet common societal challenges. The investment in GoCo Health Innovation City will strength our position even further and make the West Sweden region a world-leading health innovation cluster,” says Minister Ibrahim Baylan.
International competition is intensifying, and GoCo Health Innovation City’s ambition is to position Sweden, and foremost West Sweden, as a magnet for the best expertise and the most innovative companies in life science and health.
“Today’s ground breaking is the realization of a bold vision that AstraZeneca set three years ago to co-develop a new, world-class health innovation cluster in West Sweden. We are very pleased to welcome Fujirebio and look forward to an exciting future for GoCo Health Innovation City and for life science in Sweden,” said Katarina Ageborg, AstraZeneca EVP Sustainability and President, AstraZeneca AB.
Together, the design agency Doberman Group, the urban development agency Gehl, Mölndal City, and others created the detailed plan for GoCo Health Innovation City in record time.
For further information, please contact:
Peder Wahlgren, CEO of GoCo Development AB
0705 17 11 47
Christina Hall, CEO Fujirebio Diagnostics
0709 63 29 90